Study to Determine the Effectiveness of Risperidone in Bipolar Disorder in Children and Adolescents
Research on the Effectiveness of Risperidone in Bipolar Disorder in Adolescents and Children (REACH): A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Risperidone for the Treatment of Acute Mania in Bipolar I Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current primary diagnosis of bipolar I disorder, mania or mixed type
- Aged between 10 and 17 years
- Young Mania Rating Scale score greater than or equal to 20 at screening and baseline
Exclusion Criteria:
- Known or suspected history of substance dependence
- Significant risk for suicidal or violent behavior
- Received electroconvulsive treatment within 4 weeks of baseline
- Received a depot antipsychotic within 2 treatment cycle before baseline
- Is unable to swallow medication taken in the form of tablets
- Has a positive result for a urine drug screen done at baseline
- Known or suspected seizure disorder
- Hypothyroidism or hyperthyroidism, unless stabilized on appropriate medication for at least 3 months before screening
- Known or suspected history of hypersensitivity or intolerance to risperidone
- History of a poor antimanic response to risperidone when used in adequate doses for an adequate period as the sole antimanic agent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
The change in the total YMRS score from baseline at the 3-week endpoint
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Effects on secondary efficacy variables (YMRS response and onset of maintained response, Clinical Global Impression Scale - Bipolar Disorder [CGI-BP]), safety, tolerability, and pharmacokinetics.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Bipolar and Related Disorders
- Disease
- Bipolar Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Risperidone
Other Study ID Numbers
Other Study ID Numbers
- CR003631
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.